BackZenas BioPharma Overview

Zenas BioPharma Long Term Debt

Zenas BioPharma's long-term debt is $220M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$222.98M
↑ 103610.70% YoYΔ $222.76M vs prior year quarter

Peer trimmed avg / median

Loading

Zenas BioPharma Long Term Debt History

Loading

Zenas BioPharma vs. peers: Long Term Debt Comparison

Loading

Zenas BioPharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zenas BioPharma (ZBIO) FAQ

As of the most recent data (June 2026), ZBIO shows a long-term debt of $220M. That compares with $220K in the prior-year period — up 103610.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZBIO's long-term debt is now $220M (was $220K) — a 103610.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Zenas BioPharma is outperforming or lagging.

Tracking ZBIO's long-term debt over time shows whether Zenas BioPharma is scaling, shrinking, or reshaping that part of the business. The current reading is $220M That compares with $220K in the prior-year period — up 103610.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Zenas BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $220M) with ownership activity and broader fundamentals.

Zenas BioPharma's long-term debt is $220M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.